Publication
Prognostic factors for patients with relapsed or refractory multiple myeloma who are initiating a fourth or later line car T-cell or bispecific antibody therapy: a systematic literature review and meta-analysis.
Krina Patel, Ken Hasegawa, Jie Ting, Surbhi Sidana, Michael J Zoratti, David Wennersbusch, Steve Kanters, Ana Kostic, Taha Itani, Doris K Hansen
- Source
- PubMed
- Retrieved
- Sep 10, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260910-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
INTRODUCTION: Multiple myeloma is associated with substantial disease burden and frequent relapses, despite therapeutic advances. As evidence for chimeric antigen receptor (CAR) T-cell and bispecific antibody (BsAb) therapies is dominated by single-arm trials and real-world studies, understanding…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available